Diabetes Metab J.  2023 Sep;47(5):632-642. 10.4093/dmj.2023.0135.

Dyslipidemia Fact Sheet in South Korea, 2022

• Jin ES
• Shim JS
• Kim SE
• Bae JH
• Kang S
• Won JC
• Shin MJ
• Jin HY
• Moon J
• Lee H
• Kim HC
• Jeong IK
• on Behalf of the Committee of Public Relation of the Korean Society of Lipid and Atherosclerosis

• KMID: 2546122
• DOI: http://doi.org/10.4093/dmj.2023.0135

Abstract

Background
This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by the Korean Society of Lipid and Atherosclerosis under the name Dyslipidemia Fact Sheet 2022.
Methods
We analyzed the lipid profiles, age-standardized and crude prevalence, management status of hypercholesterolemia and dyslipidemia, and health behaviors among Korean adults aged ≥20 years, using the Korea National Health and Nutrition Examination Survey data between 2007 and 2020.
Results
In South Korea, the crude prevalence of hypercholesterolemia (total cholesterol ≥240 mg/dL or use of a lipid-lowering drug) in 2020 was 24%, and the age-standardized prevalence of hypercholesterolemia more than doubled from 2007 to 2020. The crude treatment rate was 55.2%, and the control rate was 47.7%. The crude prevalence of dyslipidemia—more than one out of three conditions (low-density lipoprotein cholesterol ≥160 or the use of a lipid-lowering drug, triglycerides ≥200, or high-density lipoprotein cholesterol [HDL-C] [men and women] <40 mg/dL)—was 40.2% between 2016 and 2020. However, it increased to 48.2% when the definition of hypo-HDL-cholesterolemia in women changed from <40 to <50 mg/dL.
Conclusion
Although the prevalence of hypercholesterolemia and dyslipidemia has steadily increased in South Korea, the treatment rate remains low. Therefore, continuous efforts are needed to manage dyslipidemia through cooperation between the national healthcare system, patients, and healthcare providers.

Keyword

Cholesterol; Disease management; Dyslipidemias; Health behavior; Prevalence; Republic of Korea

Figure

• 

  Fig. 1. (A) Age-standardized mean blood lipid concentrations. Age-standardized to the 2005 population. Data source from Korea National Health and Nutrition Examination Survey (KNHANES) 2007 to 2020. (B) Blood lipid concentration distributions in men (blue) and women (red). Data from 2016 to 2020 KNHANES; adults aged 20 years and older. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol.

• 

  Fig. 2. Prevalence of hypercholesterolemia. (A) Age-standardized prevalence of hypercholesterolemia. Standardized for the 2005 Korean population. (B) Crude prevalence of hypercholesterolemia. Data from 2007 to 2020 Korea National Health and Nutrition Examination Survey; adults aged 20 years or older. Hypercholesterolemia: total cholesterol ≥240 mg/dL or taking a lipid-lowering drug.

• 

  Fig. 3. Management of hypercholesterolemia. Summary of awareness, treatment, and control rates. Data from 2019 to 2020 Korea National Health and Nutrition Examination Survey; adults aged 20 years or older with hypercholesterolemia. Hypercholesterolemia: total cholesterol ≥240 mg/dL or use of a lipid-lowering drug. Awareness: self-reported physician-diagnosed hypercholesterolemia or dyslipidemia. Treatment: self-reported use of a lipid-lowering drug. Control: total cholesterol level <200 mg/dL.

• 

  Fig. 4. Prevalence of dyslipidemia. (A) Age-standardized prevalence of dyslipidemia. Data from 2007 to 2020 Korea National Health and Nutrition Examination Survey (KNHANES); adults aged 20 years or older. (B) Crude prevalence of dyslipedemia according to sex and age. Data from 2016 to 2020 KNHANES; adults aged 20 years or older. Dyslipidemia 1: hyper-low-density lipoprotein (LDL) cholesterolemia, hypertriglyceridemia, or hypo-high-density lipoprotein (HDL) cholesterolemia (<40 mg/dL in both men and women). Dyslipidemia 2: hyper-LDL-cholesterolemia, hypertriglyceridemia, or hypo-HDL-cholesterolemia (<40 mg/dL in men and <50 mg/dL in women).

• 

  Fig. 5. Prevalence of dyslipidemia in specific populations. (A) Prevalence of dyslipidemia according to diabetes status. Data from 2016 to 2020 Korea National Health and Nutrition Examination Survey (KNHANES); adults aged 20 years or older. Prediabetes: fasting glucose 100–125 mg/dL or glycosylated hemoglobin (HbA1c) 5.7%–6.4%. Diabetes: fasting glucose ≥126 mg/dL, HbA1c ≥6.5%, previously diagnosed or taking glucose-lowering drugs or insulin. Dyslipidemia: low-density lipoprotein cholesterol (LDL-C) ≥160 mg/dL, triglyceride ≥200 mg/dL, high-density lipoprotein cholesterol (HDL-C) <40 mg/dL, or the use of a lipidlowering drug. (B) Prevalence of dyslipidemia according to the hypertension status. Data: 2016 to 2020 KNHANES; adults aged 20 years. Prehypertension: systolic blood pressure (SBP) 120–139 mm Hg or diastolic blood pressure (DBP) 80–89 mm Hg. Hypertension: SBP ≥140 mm Hg, DBP ≥90 mm Hg, or use of a blood pressure-lowering drug. Dyslipidemia: LDL-C ≥160 mg/dL, triglyceride ≥200 mg/dL, HDL-C <40 mg/dL, or the use of a lipid-lowering drug. (C) Prevalence of dyslipidemia according to the obesity status. Data from 2016 to 2020 KNHANES; adults aged 20 years or older. Dyslipidemia: LDL-C ≥160 mg/dL, triglyceride ≥200 mg/dL, HDL-C <40 mg/dL, or the use of a lipid-lowering drug. (D) Prevalence of dyslipidemia according to abdominal obesity. Data from 2016 to 2020 KNHANES; adults aged 20 years or older. Abdominal obesity was defined as waist circumference ≥90 cm in men, ≥85cm in women. BMI, body mass index. aDyslipidemia: LDL-C ≥100 mg/dL, triglyceride ≥200 mg/dL, HDLC <40 mg/dL, or taking a lipid-lowering drug, bDyslipidemia: LDL-C ≥130 mg/dL, triglyceride ≥200 mg/dL, HDL-C <40 mg/ dL, or taking a lipid-lowering drug.

• 

Reference

1. Rhee EJ, Kim HC, Kim JH, Lee EY, Kim BJ, Kim EM, et al. 2018 Guidelines for the management of dyslipidemia in Korea. J Lipid Atheroscler. 2019; 8:78–131.

2. World Health Organization. Fact sheets: cardiovascular diseases (CVDs). Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (cited 2023 Jul 10).

3. Cho SMJ, Lee H, Lee HH, Baek J, Heo JE, Joo HJ, et al. Dyslipidemia fact sheets in Korea 2020: an analysis of nationwide population-based data. J Lipid Atheroscler. 2021; 10:202–9.

4. Kweon S, Kim Y, Jang MJ, Kim Y, Kim K, Choi S, et al. Data resource profile: the Korea National Health and Nutrition Examination Survey (KNHANES). Int J Epidemiol. 2014; 43:69–77.

5. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18:499–502.

6. Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, et al. 2018 Korean Society for the Study of Obesity guideline for the management of obesity in Korea. J Obes Metab Syndr. 2019; 28:40–5.

7. Yun S, Park S, Yook SM, Kim K, Shim JE, Hwang JY, et al. Development of the Korean Healthy Eating Index for adults, based on the Korea National Health and Nutrition Examination Survey. Nutr Res Pract. 2022; 16:233–47.

8. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41:111–88.

9. Yang YS, Kim HL, Kim SH, Moon MK. Lipid management in Korean people with type 2 diabetes mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. Diabetes Metab J. 2023; 47:1–9.

10. Yang YS, Han BD, Han K, Jung JH, Son JW; Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity. Obesity fact sheet in Korea, 2021: trends in obesity prevalence and obesity-related comorbidity incidence stratified by age from 2009 to 2019. J Obes Metab Syndr. 2022; 31:169–77.

11. Wilson PW, Grundy SM. The metabolic syndrome: a practical guide to origins and treatment: Part II. Circulation. 2003; 108:1537–40.

12. Williams CM. Lipid metabolism in women. Proc Nutr Soc. 2004; 63:153–60.

13. Hur KY, Moon MK, Park JS, Kim SK, Lee SH, Yun JS, et al. 2021 Clinical practice guidelines for diabetes mellitus of the Korean Diabetes Association. Diabetes Metab J. 2021; 45:461–81.

14. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022; 399:394–405.